Samir Sahoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samir Sahoo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- S. Renuka Jyothi
Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, India
3 shared publications - Abdulkareem Shareef
Ahl Al Bayt University, Kerbala, Iraq
2 shared publications - Ahmed Yaseen
Gilgamesh Ahliya University, Baghdad, Iraq
2 shared publications - Hayder Naji Sameer
Collage of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq
2 shared publications - Jaafaru Sani Mohammed
Medical Analysis Department, Tishk International University, Erbil, Iraq
2 shared publications Mohaned Adil
Pharmacy College, Al-Farahidi University, Baghdad, Iraq
2 shared publications
Latest Publications
- 1 June 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 591, 121131
Ferroptosis in cancer: integrating multi-omics, AI-driven biomarkers, and translational challenges
- 1 June 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 591, 121131
Ferroptosis in cancer: integrating multi-omics, AI-driven biomarkers, and translational challenges
- 28 May 2026
- Published by Springer Nature in Current Psychology
- Vol. 45 (10) , 1010
The efficacy of probiotics, prebiotics, and synbiotics in depression and anxiety: an umbrella review of clinical trials
- 28 May 2026
- Published by Springer Nature in Current Psychology
- Vol. 45 (10) , 1010
The efficacy of probiotics, prebiotics, and synbiotics in depression and anxiety: an umbrella review of clinical trials
- Open Access
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessUbiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract
- Open Access
- 28 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review
The intricate interplay within the tumor microenvironment (TME) significantly dictates the trajectory of cancer progression and therapeutic response. In HER2-positive breast cancer, a particularly aggressive subtype, cancer-associated fibroblasts (CAFs) emerge as pivotal stromal components, actively orchestrating malignant behaviors. Concurrently, microRNAs (miRNAs), small non-coding RNAs, serve as potent post-transcriptional regulators and critical mediators of intercellular communication, often encapsulated within exosomes. This review provides a comprehensive analysis of the reciprocal miRNA-mediated modulation between HER2-positive breast cancer cells and CAFs. It elucidates how tumor cell-derived miRNAs reprogram normal fibroblasts into pro-tumorigenic CAFs, and how CAF-derived miRNAs, in turn, influence HER2-positive cancer cell proliferation, invasion, metastasis, and crucially, resistance to HER2-targeted therapies. Understanding this dynamic axis reveals a self-sustaining feedback loop that drives disease advancement and therapeutic evasion. This synthesis underscores the immense potential of targeting these complex miRNA-CAF interactions as a novel strategy for diagnostic, prognostic, and therapeutic interventions, aiming to overcome the persistent challenge of resistance in HER2-positive breast cancer.
- 28 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review
The intricate interplay within the tumor microenvironment (TME) significantly dictates the trajectory of cancer progression and therapeutic response. In HER2-positive breast cancer, a particularly aggressive subtype, cancer-associated fibroblasts (CAFs) emerge as pivotal stromal components, actively orchestrating malignant behaviors. Concurrently, microRNAs (miRNAs), small non-coding RNAs, serve as potent post-transcriptional regulators and critical mediators of intercellular communication, often encapsulated within exosomes. This review provides a comprehensive analysis of the reciprocal miRNA-mediated modulation between HER2-positive breast cancer cells and CAFs. It elucidates how tumor cell-derived miRNAs reprogram normal fibroblasts into pro-tumorigenic CAFs, and how CAF-derived miRNAs, in turn, influence HER2-positive cancer cell proliferation, invasion, metastasis, and crucially, resistance to HER2-targeted therapies. Understanding this dynamic axis reveals a self-sustaining feedback loop that drives disease advancement and therapeutic evasion. This synthesis underscores the immense potential of targeting these complex miRNA-CAF interactions as a novel strategy for diagnostic, prognostic, and therapeutic interventions, aiming to overcome the persistent challenge of resistance in HER2-positive breast cancer.
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 76
Exosomal non-coding RNAs as emerging drivers of immune dysregulation in melanoma
Melanoma is a type of skin cancer that starts in melanocytes. It is estimated to increase by 2050 based on prediction studies. Exosomes have been identified as crucial intracellular mediators by carrying the donor-derived cargoes from stromal cells, immune cells, and even tumor cells, thereby affecting the function of recipient cells in a context-dependent manner. Although EVs can transport biologically active compounds like proteins, lipids, RNA, and DNA, their exact role remains unclear. The past few years have seen a surge in studies on tumor-associated cargo in exosomes, particularly concerning ncRNAs. The function of exosomal non-coding RNAs in melanoma’s immunopathogenesis has been reviewed in detail in the current narrative review article. Exosomal ncRNAs have the potential to develop novel diagnostic and therapeutic targets in melanoma.
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 76
Exosomal non-coding RNAs as emerging drivers of immune dysregulation in melanoma
Melanoma is a type of skin cancer that starts in melanocytes. It is estimated to increase by 2050 based on prediction studies. Exosomes have been identified as crucial intracellular mediators by carrying the donor-derived cargoes from stromal cells, immune cells, and even tumor cells, thereby affecting the function of recipient cells in a context-dependent manner. Although EVs can transport biologically active compounds like proteins, lipids, RNA, and DNA, their exact role remains unclear. The past few years have seen a surge in studies on tumor-associated cargo in exosomes, particularly concerning ncRNAs. The function of exosomal non-coding RNAs in melanoma’s immunopathogenesis has been reviewed in detail in the current narrative review article. Exosomal ncRNAs have the potential to develop novel diagnostic and therapeutic targets in melanoma.
- 26 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 1-20
The emerging role of miR-362 in cancer: expression and function across different cancer types
MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression involved in a broad range of biological activities. Recent studies have increasingly highlighted their significant role in the development and progression of various human cancers. Among these, miR-362 has emerged as a context-dependent molecule, exhibiting both oncogenic and tumor-suppressive functions across different malignancies. Elevated levels of miR-362 have been associated to tumor-promoting effects in several cancers. In contrast, its downregulation in some other carcinoma is associated with disease progression, suggesting a tumor-suppressive role. These opposing functions underscore miR-362 involvement in complex regulatory networks and supports its potential as a biomarker for diagnosis, prognosis, and possibly therapeutic intervention. This review aims to provide an overview of the current understanding of miR-362 expression patterns, molecular targets, regulatory mechanisms, and its dual role in cancer biology, with the goal of clarifying its clinical significance in cancer diagnosis, prognosis, and therapy. Graphical Abstract The specific targets of miR-362 across various malignancies
- 26 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 1-20
The emerging role of miR-362 in cancer: expression and function across different cancer types
MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression involved in a broad range of biological activities. Recent studies have increasingly highlighted their significant role in the development and progression of various human cancers. Among these, miR-362 has emerged as a context-dependent molecule, exhibiting both oncogenic and tumor-suppressive functions across different malignancies. Elevated levels of miR-362 have been associated to tumor-promoting effects in several cancers. In contrast, its downregulation in some other carcinoma is associated with disease progression, suggesting a tumor-suppressive role. These opposing functions underscore miR-362 involvement in complex regulatory networks and supports its potential as a biomarker for diagnosis, prognosis, and possibly therapeutic intervention. This review aims to provide an overview of the current understanding of miR-362 expression patterns, molecular targets, regulatory mechanisms, and its dual role in cancer biology, with the goal of clarifying its clinical significance in cancer diagnosis, prognosis, and therapy. Graphical Abstract The specific targets of miR-362 across various malignancies
- 19 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-27
Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy
Exosomes (30–150 nm) are small extracellular vesicles that are secreted by cells into the extracellular environment and are known to mediate cell-to-cell communication. Exosomes contain proteins, lipids, and RNA molecules in relative abundance, capable of modifying the activity of target cells. Melanoma-derived exosomes (MEXs) promote the transfer of oncogenic signals and immunosuppressive factors into immune cells, resulting in a bias of the immune response towards tumor-promoting processes. MEXs could suppress the activation and proliferation of T cells and dendritic cells and induce differentiation of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). They can induce apoptosis of antigen-specific CD8 + T cells and promote the transfer of tumor antigens, resulting in immune evasion. Specifically, MEXs can shuttle cytokines like interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) to immune cells or express programmed death-ligand 1 (PD-L1 or CD274), creating an immune-suppressive microenvironment that promotes tumorigenesis. Since exosomes preferentially accumulate in melanoma tissues, this targeted delivery could enhance the bioavailability of treatments while limiting side effects. Here, we review the molecular composition of melanoma-derived exosomes, their mechanisms of action, and their potential as therapeutic targets or biomarkers in melanoma. The summarizations of these mechanisms to appropriately influence exosome-mediated interactions could yield new tactics to elicit anti-melanoma immunity or augment the therapeutic effects of current therapies.
- 19 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-27
Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy
Exosomes (30–150 nm) are small extracellular vesicles that are secreted by cells into the extracellular environment and are known to mediate cell-to-cell communication. Exosomes contain proteins, lipids, and RNA molecules in relative abundance, capable of modifying the activity of target cells. Melanoma-derived exosomes (MEXs) promote the transfer of oncogenic signals and immunosuppressive factors into immune cells, resulting in a bias of the immune response towards tumor-promoting processes. MEXs could suppress the activation and proliferation of T cells and dendritic cells and induce differentiation of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). They can induce apoptosis of antigen-specific CD8 + T cells and promote the transfer of tumor antigens, resulting in immune evasion. Specifically, MEXs can shuttle cytokines like interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) to immune cells or express programmed death-ligand 1 (PD-L1 or CD274), creating an immune-suppressive microenvironment that promotes tumorigenesis. Since exosomes preferentially accumulate in melanoma tissues, this targeted delivery could enhance the bioavailability of treatments while limiting side effects. Here, we review the molecular composition of melanoma-derived exosomes, their mechanisms of action, and their potential as therapeutic targets or biomarkers in melanoma. The summarizations of these mechanisms to appropriately influence exosome-mediated interactions could yield new tactics to elicit anti-melanoma immunity or augment the therapeutic effects of current therapies.